Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
63 participants
INTERVENTIONAL
2021-10-25
2032-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
NCT03712878
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
NCT04191187
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
NCT01384513
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
NCT01350258
Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia
NCT00961142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the 2 year cumulative incidence of TRM in patients undergoing reduced intensity conditioning (RIC) haploidentical (HI) HSCT in this protocol.
SECONDARY OBJECTIVES:
I. To assess the 2 year cumulative incidence of relapse in patients undergoing RIC HI HSCT in this protocol.
II. To assess the consistency and pace of engraftment. III. To assess the pace of T cell and B cell immune recovery. IV. To assess the incidence and severity of graft versus host disease (GVHD).
OUTLINE: Patients are assigned to 1 of 2 cohorts.
RADIATION-BASED COHORT: Patients receive fludarabine intravenously (IV) on days -11, -10, -9, and -8, undergo total-body irradiation (TBI) twice a day (BID) on days -10 and -9, undergo donor lymphocyte infusion (DLI) on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.
CHEMOTHERAPY-BASED COHORT: Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.
After completion of study treatment, patients are followed for 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Radiation-Based Cohort (fludarabine, TBI, infusion)
Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.
Fludarabine
Given IV
Total-Body Irradiation
Undergo TBI
Donor Lymphocyte Infusion
Undergo DLI
Cyclophosphamide
Given IV
Tacrolimus
Given IV
Mycophenolate Mofetil
Given IV
Hematopoietic Cell Transplantation
Undergo HSCT
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/ biopsy
Diagnostic Imaging
Undergo diagnostic imaging
Biospecimen Collection
Undergo blood sample collection
Arm 2: Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)
Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.
Fludarabine
Given IV
Total-Body Irradiation
Undergo TBI
Donor Lymphocyte Infusion
Undergo DLI
Cyclophosphamide
Given IV
Tacrolimus
Given IV
Mycophenolate Mofetil
Given IV
Hematopoietic Cell Transplantation
Undergo HSCT
Melphalan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/ biopsy
Diagnostic Imaging
Undergo diagnostic imaging
Biospecimen Collection
Undergo blood sample collection
Arm 3: HLA- Identical cohort (radiation-based or chemotherapy-based conditioning)
This group (HLA- Identical cohort), which is expected to be small, can undergo HSCT with radiation-based or chemotherapy-based conditioning. Due to small numbers of patients with available HLA identical related donors, this third, descriptive arm is included so that this group, too small in number for a free-standing study, are treated on clinical trial. This is also a separate arm of the study and the outcome of patients treated on this arm will be analyzed descriptively without statistical comparison or power analysis.
Fludarabine
Given IV
Total-Body Irradiation
Undergo TBI
Donor Lymphocyte Infusion
Undergo DLI
Cyclophosphamide
Given IV
Tacrolimus
Given IV
Mycophenolate Mofetil
Given IV
Hematopoietic Cell Transplantation
Undergo HSCT
Melphalan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/ biopsy
Diagnostic Imaging
Undergo diagnostic imaging
Biospecimen Collection
Undergo blood sample collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fludarabine
Given IV
Total-Body Irradiation
Undergo TBI
Donor Lymphocyte Infusion
Undergo DLI
Cyclophosphamide
Given IV
Tacrolimus
Given IV
Mycophenolate Mofetil
Given IV
Hematopoietic Cell Transplantation
Undergo HSCT
Melphalan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/ biopsy
Diagnostic Imaging
Undergo diagnostic imaging
Biospecimen Collection
Undergo blood sample collection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute myeloid leukemia
* Acute lymphoid leukemia in remission
* Myelodysplasia (MDS)
* Chronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement
* Multiple myeloma
* Chronic myeloid leukemia
* Myelofibrosis
* Myeloid malignancy not otherwise specified
* Chronic myelomonocytic leukemia
* Essential thrombocytopenia or polycythemia vera
* T cell leukemia
* T cell lymphoma without significant lymph node disease burden
* Any hematological malignancy or dyscrasia not cited above in which HSCT is potentially curable
* Any patient who has a hematological disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding total-body irradiation (TBI), or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.
* Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)
* Chemotherapy-based cohort diagnoses:
* Hodgkin or non-Hodgkin lymphoma
* Small lymphocytic lymphoma/CLL
* Any other diagnosis in which chemotherapy is thought to be superior to radiotherapy for treatment of the disease
* Hematological malignancy in patients who cannot receive \> 2 Gy radiation
* Aplastic anemia and other non-malignant hematologic dyscrasias
* Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)
* Human leukocyte antigen (HLA) identical cohort diagnoses:
\* Patients in this group will be treated in parallel to the radiation-based cohort or the chemotherapy-based group based on what category their diagnosis falls into. However, these patients will have HLA identical related donors (one-antigen cross-over event included).
* Left ventricular ejection fraction of \>= 50%
* Diffusion lung capacity of oxygen \>= 50% and forced expiratory volume at 1 second \>= 50% of predicted corrected for hemoglobin
* Serum bilirubin =\< 1.8
* Aspartate aminotransferase or alanine aminotransferase =\< 2.5 x upper limit of normal
* Creatinine clearance of \>= 60 mL/min
* Patients must have adequate Karnofsky performance status (KPS) and Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) scores:
* Patients \< age 60 years must have a KPS of \>= 60% and an HCT-CI score of 5 or less
* Patients aged 60 to 65 years must have a KPS of \>= 60% and an HCT-CI score of 4 or less
* Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less
* Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less
* (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator (PI) and at least 1 co-investigator (CI) not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities
* Patients must be willing to use contraception if they have childbearing potential
* Patient or patient's guardian is able to give informed consent
* Patients should have a life expectancy of \>= 6 months for reasons other than their underlying hematologic/oncologic disorder
* Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
* Patients should not be:
* Human immunodeficiency virus positive
* Have active involvement of the central nervous system with malignancy. This can be documented by a normal neurological exam, magnetic resonance imaging (MRI) of the head, and/or a negative cerebral spinal fluid analysis
* Pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Jefferson University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Usama Gergis, MD
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadephia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JT 15545
Identifier Type: OTHER
Identifier Source: secondary_id
21D.466
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.